CAPhO 2024 Sponsored Symposium AbbVie Corporation - The Role of Pharmacists in Management of Bispecific Antibody Related Immune-mediated Adverse Events in R/R LBCL and in Supporting Access to Novel Cancer Treatments
Details
Through this presentation, pharmacists will explore the current treatment landscape for patients with relapsed/refractory (R/R) large B cell lymphoma (LBCL) in Canada, their role in managing immune-mediated adverse events with bispecific antibodies, and the importance of pharmacists in the successful adoption of novel cancer medications in academic and community hospital settings.
The Leukemia & Lymphoma Society of Canada will also contribute to this presentation by outlining the role oncology pharmacists can take to enable access to novel cancer treatments.
Learning Objectives:
- Review the evolving R/R LBCL treatment landscape
- Describe management of immune-mediated adverse events with bispecific antibodies (e.g., cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome)
- Discuss how pharmacists can utilize their clinical expertise to ensure timely and safe adoption of novel cancer medications in the academic and community hospital settings
- Explain the role oncology pharmacists can plan in enabling access to novel cancer treatments
Sponsored by AbbVie Corporation
